Letters of intent (LOI’s) are sought from academic or industry applicants with innovative approaches to:
- identify novel targets for therapeutics to improve metabolic control in T1D,
- validate novel targets for therapeutics to improve metabolic control in T1D, or
- perform clinical research on T1D pathophysiology (including studies on selected human tissues) that will facilitate the discovery or validation of novel targets in future studies.
Funding & Duration
Each application may request up to USD $200,000 (approx. AUD $273,000) per year (including up to 10% indirect costs), for up to two years.
Applications may be submitted by domestic and foreign non-profit organisations, public and private, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government. Applicants must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent and have a faculty position or equivalent at a college, university, medical school, or other research facility.
Please note that applications from for-profit entities or industry collaborations with academia may be submitted, however, additional information will be requested from for-profit entities if a full application is invited.
There are no citizenship requirements for this program. To assure continued excellence and diversity among applicants and awardees, JDRF welcomes applications from all qualified individuals and encourages applications from persons with disabilities, women, and members of minority groups underrepresented in the sciences.
Submission Requirements & Due Dates
- 1 October – Letter of Intent (LOI) submitted directly to Sponsor
- 21 November – full applications submitted for internal review.
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review